This breakthrough coronavirus treatment developed by Prof. Nadir Arber at Tel Aviv’s Sourasky Medical Center has successfully completed phase 2 trials and has helped numerous moderate-to-serious cases of COVID-19 to quickly recover from the disease.
The treatment uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which Prof. Arber of TASMC has spent decades researching.
This new medicine fights the cytokine storm — a potentially lethal immune overreaction to the coronavirus infection that is believed to be responsible for much of the deaths associated with the disease.
90% of patients treated with this new drug were discharged in 5 days.
